ADC Therapeutics (ADCT) Other Non-Current Liabilities (2020 - 2026)

ADC Therapeutics (ADCT) has reported Other Non-Current Liabilities for 7 consecutive years, with $304.7 million the latest figure, recorded in Q1 2026.

• Quarterly Other Non-Current Liabilities fell 6.76% year-over-year to $304.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $304.7 million (down 6.76% YoY) and the FY2025 annual result came in at $322.5 million, up 0.76% from the prior year.
• Other Non-Current Liabilities eased to $304.7 million in Q1 2026 per ADCT's latest filing, from $322.5 million in the prior quarter.
• Over the last five years, Other Non-Current Liabilities for ADCT reached as high as $340.2 million in Q3 2025 and fell as low as $204.1 million in Q1 2022.
• A 5-year average of $285.3 million and a median of $305.3 million in 2023 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2023 — Other Non-Current Liabilities surged 46.61% — and 2026, when it retreated 6.76%.
• Year by year, Other Non-Current Liabilities stood at $212.4 million in 2022, then soared by 42.96% to $303.6 million in 2023, then increased by 5.44% to $320.1 million in 2024, then gained by 0.76% to $322.5 million in 2025, then fell by 5.53% to $304.7 million in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $304.7 million, $322.5 million, and $340.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.